PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9660842-2	1998	At therapeutic concentrations (steady-state plasma concentrations approximately 4 microM), nelfinavir was found to be a competitive inhibitor of only testosterone 6beta-hydroxylase (CYP3A4) with a Ki concentration of 4.	Nelfinavir	91-101	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	182-188	
9660842-4	1998	At supratherapeutic concentrations, nelfinavir competitively inhibited dextromethorphan O-demethylase (CYP2D6), S-mephenytoin 4-hydroxylase (CYP2C19), and phenacetin O-deethylase (CYP1A2) with Ki concentrations of 68, 126, and 190 microM, respectively.	Nelfinavir	36-46	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	103-109	
9660842-4	1998	At supratherapeutic concentrations, nelfinavir competitively inhibited dextromethorphan O-demethylase (CYP2D6), S-mephenytoin 4-hydroxylase (CYP2C19), and phenacetin O-deethylase (CYP1A2) with Ki concentrations of 68, 126, and 190 microM, respectively.	Nelfinavir	36-46	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	112-139	
9660842-4	1998	At supratherapeutic concentrations, nelfinavir competitively inhibited dextromethorphan O-demethylase (CYP2D6), S-mephenytoin 4-hydroxylase (CYP2C19), and phenacetin O-deethylase (CYP1A2) with Ki concentrations of 68, 126, and 190 microM, respectively.	Nelfinavir	36-46	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	141-148	
9660842-4	1998	At supratherapeutic concentrations, nelfinavir competitively inhibited dextromethorphan O-demethylase (CYP2D6), S-mephenytoin 4-hydroxylase (CYP2C19), and phenacetin O-deethylase (CYP1A2) with Ki concentrations of 68, 126, and 190 microM, respectively.	Nelfinavir	36-46	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	180-186	
9660842-6	1998	The inhibitory potency of nelfinavir toward CYP3A4 suggested the possibility of in vivo inhibition of this isoform, whereas in vivo inhibition of other P450s was considered unlikely.	Nelfinavir	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-50	
9660842-7	1998	In a one-sequence crossover study in 12 healthy volunteers, nelfinavir inhibited the elimination of the CYP3A substrate terfenadine and the carboxylate metabolite of terfenadine.	Nelfinavir	60-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	104-109	
9660842-8	1998	The 24-hr urinary recoveries of 6beta-hydroxycortisol were reduced by an average of 27% during nelfinavir treatment, consistent with CYP3A inhibition by nelfinavir.	Nelfinavir	153-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-138	
9660842-9	1998	Inhibition of CYP3A4 by nelfinavir in vitro was NADPH-dependent requiring the catalytic formation of a metabolite or a metabolic intermediate.	Nelfinavir	24-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20	
9660842-12	1998	Although incubations with nelfinavir showed a time- and concentration-dependent loss of CYP3A4 activity, the partial or complete recovery of enzyme activity upon dialysis indicated that inhibition was reversible.	Nelfinavir	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94	
9660842-15	1998	Collectively, these results suggest that the probable mechanism for CYP3A4 inhibition by nelfinavir is a transient metabolic intermediate or stable metabolite that coordinates tightly but reversibly to the heme moiety of the P450.	Nelfinavir	89-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-74